Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas
14 vistas
• 07/18/23
0
0
Empotrar
administrator
Suscriptores
Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios